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Meloxicam (MLX) is a non-steroidal, anti-inflammatory drug that is prescribed in the treatment of 
rheumatoid arthritis and osteoarthritis. MLX is practically insoluble in water and exhibits a slow onset 
of action. In this study, MLX solid dispersions (MLX SDs) were prepared to improve the water solubility 
of this poorly water-soluble drug. Then orally disintegrating tablets (ODT) of MLX were developed 
using MLX SD to decrease the onset of action of this drug. MLX, poloxamer 188, and crospovidone of 
different ratios were melted in molten poloxamer 188 as a hydrophilic carrier. The optimum SD with 
the highest saturation solubility in water (13.09±0.34 microgram/mL) consisting of MLX: poloxamer 
188: crospovidone in the ratio of 1:2:0 was used for the preparation of MLX ODTs. MLX ODTs were 
prepared by the direct compression method and optimized by the 23 factorial design. The effect of 
the superdisintegrant concentration, the mannitol–avicel ratio, and the level of compression force on 
the disintegration time, hardness, and percent of dissolved MLX from MLX ODTs after 30 min was 
evaluated. DSC and XRD analysis approved an amorphous form of MLX in SDs. The optimized ODT 
formulation containing 10% of superdisintegrant, and mannitol and avicel in the ratio of 4:1 respectively 
was compressed using a high level of compression force. The optimized ODT showed hardness (34.37±2.1 
N) and friability (1.26±0.04%). This formulation showed a rapid disintegration in 12.66±2.5 seconds, 
which 82.66±5.1% of the MLX released within 30 min. MLX ODTs, prepared from MLX SD, could be 
introduced as a suitable dosage form of MLX with improved solubility and the onset of action.
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INTRODUCTION 
Meloxicam (MLX) is a non-steroidal anti-
inflammatory drug that is prescribed in the treatment 
of rheumatoid arthritis and osteoarthritis with low 
gastrointestinal complications (Pairet et al., 1998; Distel 
et al., 1996; Ahmed, Khanna, Furst, 2005; Aoki et al., 
2006). MLX is practically insoluble in water (belonging 
to BCS Class II) and exhibits a slow oral absorption and 
slow onset of action (Budavari et al., 2001; Ghorab et al., 
2004). A rapid onset of action is important for patients, 
particularly under the pain condition of rheumatism and 
osteoarthritis. Consequently, a suitable oral dosage form 
of MLX, with enhanced aqueous solubility, could facilitate 
its oral absorption and reduce its onset of action for the 
treatment of acute pain. Different methods such as salt 
formation (Serajuddin, 2007), emulsiﬁcation (He, He, 
Gao, 2010), and nano-pulverization (Merisko-Liversidge, 
Liversidge, Cooper, 2013) had been used to improve the 
solubility and bioavailability of poorly soluble drugs. 
The preparation of solid dispersion (SD) is a feasible and 
effective method to improve the dissolution bioavailability 
of poorly water-soluble drugs including MLX (Leuner, 
Dressman, 2000). SDs are dispersions of one or more 
active pharmaceutical ingredients (API) in an inert carrier 
or matrix such as biodegradable polymers in solid state, 
prepared by melting (fusion), solvent, or a melting–solvent 
method (Chiou, Riegelman, 1971). It has been suggested 
that orally disintegrating tablets (ODT) have a faster onset 
of action compared to conventional tablets, and are more 
appropriate for the treatment of acute pain (Rauck et al., 
2009). In addition, ODTs could reduce dysphagia in older 
patients suffering from arthritis (Shen et al., 2007). With 
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these in mind, the objective of this study was to enhance 
the solubility of MLX through the preparation of its SDs 
by the melting method and then decrease its onset of 
action by the preparation of ODTs from the prepared solid 
dispersion of this poorly water-soluble drug.
MATERIAL AND METHODS
Material 
Poloxamer188 was supplied by BASF (Germany). 
Crospovidone was purchased from Sigma-Aldrich 
(Germany). Meloxicam (MLX), mannitol, microcrystalline 
cellulose (Avicel PH-101), aspartame and magnesium 
stearate were purchased from the Farabi Pharmaceutical 
Company (Iran). All other solvents and chemicals were of 
an analytical grade.
Preparation of SD of meloxicam with 
poloxamer188 
Accurately weighed quantities of MLX and 
crospovidone in different ratios were dissolved in 
melted poloxamer 188 and mixed carefully to obtain a 
homogenous mixture. The amount of MLX, crospovidone 
and poloxamer188 utilized for the preparation of MLX 
solid dispersions (MLX SD) are mentioned in Table 
I. After the preparation of homogenous mixtures, the 
prepared mixtures were immediately cooled in ice.
Preparation of physical mixtures of MLX and 
carriers 
The physical mixtures were prepared by weighing 
the calculated amounts of MLX, poloxamer 188, and 
crospovidone in the same ratio of solid dispersion samples 
and mixing them in a mortar by triturating. The resultant 
physical mixtures were passed through a 16-mesh sieve.
Characterization of SD 
Drug content determination in SD samples
An accurately weighed amount of each solid 
dispersion sample was dissolved in 5 mL of methanol 
and, then, 1 mL of 0.1 N NaOH was added. A phosphate 
buffer of pH 7.5 was added until the volume reached 
100 mL. The resulting suspension was ﬁltered through a 
0.22-μm ﬁlter. The concentration of MLX was determined 
spectrophotometrically at 362 nm (UV mini/420 
Shimadzo, Japan). The concentration of each sample was 
determined in triplicates and the mean value and standard 
deviation were reported.
Determination of saturation solubility 
Saturation solubility studies were performed on 
pure MLX, physical mixtures, and SD samples. An excess 
amount of the samples was added to a volumetric flask 
containing 20 mL of distilled water and stirred at 100 rpm 
for 48 h at 25 °C. The resulting suspension was ﬁltered 
through a 0.22-μm filter. The concentration of MLX 
was determined spectrophotometrically at 362 nm. The 
solubility of each sample was determined in triplicates 
and the mean value and standard deviation were reported.
Differential scanning calorimetry (DSC) analysis
The thermal behaviors of MLX, poloxamer 188, 
TABLE I - The amount of MLX, poloxamer 188 and crospovidone that utilized for preparation of MLX SDs and the characteristics 
of prepared MLX SDs
Formulation MLX Poloxamer
MLX/
poloxamer 
188 ratio
Crospovidone
Saturation 
solubility 
(µg/ml)
Drug content 
%
Saturation 
solubility 
of physical 
mixture 
(µg/ml)
SD1 200 mg 200 mg 1 ----- 10.41±1.71 82.7±2.36 8.43±1.142
SD2 200 mg 400 mg 2 ----- 13.09±0.34 92.4±3.14 9.01±0.345
SD3 200 mg 800 mg 4 ----- 12.1±1.19 94.1±3.16 9.17±0.239
SD4 200 mg 200 mg 1 200 mg 2.6±0.011 74.8±4.25 7.1±0.471
SD5 200 mg 400 mg 2 200 mg 3.1±0.38 84.1±2.85 8.6±0.609
SD6 200 mg 800 mg 4 200 mg 4.3±0.305 82.5±2.45 8.79±0.61
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crospovidone, selected sample of SDs with higher 
saturation solubility and their physical mixture were 
analyzed using NETZSCH DSC 200 F3 instrument 
(NETZSCH, Germany). Five milligrams of samples were 
placed in aluminum pans. The samples were heated from 
20 to 280 °C at a scanning rate of 10 °C/min. The melting 
point and enthalpy of fusion were automatically calculated 
using the software provided. 
XRD Analysis
The crystal l ini ty of  MLX, poloxamer188, 
crospovidone, and the selected samples of SDs with higher 
saturation solubility and their physical mixture were 
evaluated with an X-ray diffractometer (Philips X’PERT, 
Germany). The diffraction patterns were measured with a 
voltage of 40 kV and a current of 30 mA. X-ray diffraction 
data were collected at room temperature in the range of 
10˚< 2θ <40˚.
Experimental design
A 23 full-factorial experimental design was applied 
to determine the optimum condition for the preparation 
of MLX orally disintegrating tablets (MLX ODTs) 
using the Design-Expert 7 software (State Ease. Inc., 
Minneapolis, MN, USA). The percent of crospovidone as a 
superdisintegrant (X1), the mannitol–avicel ratio (X2), and 
the compression force applied for tablet compression (X3) 
were selected as independent variables. Each factor was 
set at high and low levels. The actual values of different 
variables are given in Table II. Eight formulations of MLX 
ODTs (F1 to F8) were prepared according to the design as 
shown in Table II. The hardness, disintegration time, and 
the percent of meloxicam that dissolved in the dissolution 
medium after 30 min. were taken as response parameters. 
Preparation of orally disintegrating tablets (ODT)
ODT of MLX was prepared by the direct compression 
method. All ingredients were separately passed through a 
60-mesh sieve. MLX SD, mannitol, avicel, crospovidone 
(as superdisintegrant) and aspartame (as sweetener) 
were accurately weighed and properly mixed up. The 
blends were lubricated with 1% magnesium stearate. An 
evaluation of the mixed blends of MLX SD and excipients 
were carried out for angle of repose, bulk density, tapped 
density, compressibility and flowability (Lieberman, 
Lachman, 1989).
The tablets were directly compressed using a single-
punch tableting machine (Erweka AR 4100, Germany) 
equipped with a 6-mm round flat punch. The tablets were 
compressed to a target weight of 150 mg. 
Characterization of MLX ODTs
Drug content determination in tablets 
Ten tablets from each batch were weighed 
separately. Each tablet was accurately weighed, 
dissolved in 5 mL of methanol and 1 mL of 0.1 N NaOH 
and the volume was made up to 100 mL with PBS (pH 
7.5) and stirred until MLX was dissolved completely. 
The resulting suspension was ﬁltered through a 0.22-
μm ﬁlter. The concentration of MLX was determined 
spectrophotometrically at 362 nm. The result of each 
sample was determined in triplicate and the mean value 
and standard deviation were reported.
Determination of friability
A friability analysis was performed on 20 tablets at a 
speed of 25 rpm with tablets dropping from a height of six 
inches for 100 revolutions using a Roche type friabilitor 
(Erweka, TB-24, Germany). The accurate weights of the 
tablets were determined before and after the test. The 
friability was measured as a percentage of weight lost 
during a standardized abrasion. 
Tablet disintegration time
The in vitro disintegration time of MLX ODTs was 
determined using an Erweka ZT (Germany) disintegration 
apparatus with 1000 mL of puriﬁed water, maintained at 
37 ± 0.5 °C. The disintegration time was recorded once the 
tablets were completely disintegrated and passed through 
the mesh. Six tablets per formulation were tested and the 
mean value and standard deviation reported.
Tablet hardness 
The hardness of MLX ODTs was evaluated by 
individually measuring the breaking strength in the radial 
TABLE II - The actual values of different independent variables 
that used for determination of the optimum conditions for 
preparation of MLX orally disintegrating tablets
Variable High Level Low level
Percent of disintegrant 10% 5%
Mannitol/avicel ratio 4 2
Compression force High low
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direction of 8 tablets using a tablet hardness tester with an 
Erweka TBH 30 MD equipment (Germany).
Dissolution test
The release rate of MLX from MLX ODTs (n=3) 
was determined using a USP apparatus Type II at 75 
rpm (Electro lab, TDT-08L). The dissolution test was 
performed using 900 mL of phosphate buffer pH 7.5 as a 
dissolution medium, at 37 ± 0.5 °C. A sample (2 mL) of the 
dissolution medium was withdrawn from the dissolution 
vessels at 2, 5, 10, 15, 20 and 30 min and replaced with 
a fresh dissolution medium. The samples were ﬁltered 
through a 0.22-µm membrane ﬁlter. The absorbance of 
these solutions was measured at 362 nm using a Shimadzu 
spectrophotometer. The cumulative percentage of the 
release of MLX was calculated using an equation obtained 
from a standard curve.
RESULTS AND DISCUSSION
Saturation solubility of MLX SDs and physical 
mixtures
The results of the solubility studies indicated 
that pure MLX had a very low solubility in water at 
25 °C (6.58±0.21 µg/mL). The saturation solubility of 
MLX increased in the presence of poloxamer 188 and 
crospovidone in the physical mixtures. An increase in the 
concentration of poloxamer 188 in the physical mixture 
samples increased the saturation solubility of MLX. This 
phenomenon could be attributed to an improvement of 
the MLX wettability because of high water solubility of 
poloxamer 188 (Jung et al., 1999). As shown in Table I, 
MLX SDs that contain MLX and poloxamer 188 (SD1, 
SD2 and SD3) show a signiﬁcant increase in saturation 
solubility compared to the pure MLX and physical 
mixtures with the same ratios (p value<0.05). In SD1 
and SD2, the saturation solubility of MLX increased 
after the amount of poloxamer 188 was raised. This was 
because of the high water solubility of poloxamer 188 
(Jung et al., 1999). The preparation of the dosage form 
of solid dispersions (SDs) is a critical aspect that should 
be considered by scientists. The pulverization of the solid 
dispersions (SDs) prepared by the melting method is 
difficult. In addition, these SDs are often soft and tacky 
and have poor flow characteristics. Consequently, the 
addition of more excipients to the SDs is often necessary 
(Serajuddin, 1999; Leuner, Dressman, 2000; Shibata et al., 
2009). These difficulties can be overcome by the addition 
of crospovidone, as a carrier, to SDs (Fujii et al, 2005; 
Shibata et al., 2009). However, crospovidone does not 
melt or dissolve in melted poloxamer but crospovidone 
possesses several useful characteristics that can improve 
the SD proprieties when added to them. Firstly, a good 
flow property and compressibility of crospovidone can 
improve the fluidity and tableting ability of the SD powder 
(Fujii et al., 2005). Secondly, the same chemical structure 
of crospovidone and polyvinylpyrrolidone (PVP), which 
is commonly used as a carrier of SDs (Leuner, Dressman, 
2000), can improve the water solubility of poorly soluble 
drugs in SDs. 
In this study, crospovidone was added to three 
formulations of MLX SDs to improve their flow and 
compressibility properties. But the saturation solubility of 
MLX SD samples that contained crospovidone (SD4, SD5, 
and SD6) was lower than the values predicted, according 
to the saturation solubility of the physical mixtures having 
the same ratios (Table I). The lower saturation solubility 
of MLX SDs that contained crospovidone (SD4, SD5, 
and SD6) compared to the predicted value may be related 
to a decrease in the water sorption of MLX SDs due to 
MLX-crospovidone interaction in the solid dispersion. 
The interaction could decrease the number of available 
polar groups that could interact with water during the 
water sorption and dissolution phenomena. Moreover, the 
formation of the gel formed by crospovidone around the 
solid dispersions could increase the viscosity in the donor 
phase and decrease the saturation solubility of MLX (Jung 
et al., 1999; Punčochová et al., 2014).
As shown in Table 1, batch number SD2 (containing 
MLX: poloxamer 188: crospovidone in the ratio 1:2:0) 
exhibited the maximum saturation solubility equal to 
13.09±0.347 µg/mL and was used for the preparation of 
MLX ODTs. 
Drug content of MLX SDs
The prepared MLX SDs showed excellent 
entrapment of MLX. The MLX content in the solid 
dispersions was found to be in the range of 74.8±4.25 to 
94.1±3.16% as shown in Table I. Batch SD3 formulation 
(containing MLX: poloxamer 188: crospovidone in 
the ratio of 1:4:0) showed the highest drug content 
of 94.1±3.16%, while batch SD4 (containing MLX: 
poloxamer 188: crospovidone in the ratio of 1:1:1) showed 
the least drug content of 74.8±4.25%. 
Differential scanning calorimetry (DSC) analysis
A DSC analysis was performed in order to screen 
the solid-state properties of solid dispersions (SDs) and 
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physical mixture samples. This analysis could be used to 
evaluate any interaction between MLX, poloxamer 188, 
and crospovidone. The DSC thermograms of poloxamer 
188, crospovidone, pure MLX, SD2 (MLX: poloxamer 
188: crospovidone ratio=1:2:0), SD5 (MLX: poloxamer 
188: crospovidone ratio=1:2:1) and MLX, poloxamer 188, 
and crospovidone physical mixture have been depicted in 
Figure 1. MLX showed a sharp endothermic peak at 262.5 
°C, indicating its melting points. Poloxamer 188 showed a 
sharp endothermic peak at 60.6 °C, indicating its melting. 
The DSC thermogram of physical mixture showed two 
endothermic peaks at 55.4 °C and 250.5 °C, indicating the 
melting points of poloxamer 188 and MLX respectively. 
The presence of polymer in the physical mixture sample 
decreased the melting temperature of MLX and its fusion 
enthalpy, perhaps due to the miscibility of drug/polymer, 
thus resulting in a partial dissolution of MLX in polymers 
during the heating process (Jahangiri et al., 2015; Shah et al., 
2007). Furthermore, these reductions in the melting point 
and enthalpy of fusion were greater for solid dispersion 
samples (SD2 and SD5). The melting temperature of MLX 
and enthalpy of fusion were 250.5 °C and ΔH=422 J/g for 
physical mixture, while these records were 209.6 °C and 
ΔH=97.98 J/g for SD2 and 207.3 °C and ΔH=209.5 J/g for 
SD5. These results show that the method of solid dispersion 
preparation could generate a more amorphous state of MLX 
in solid dispersion samples (because of a lower melting 
point) and also produce a more homogenous matrix of 
drug/polymer compared to physical mixtures (because of a 
lower enthalpy of fusion). Similar results had been reported 
before for rofecoxib and poloxamer 188 (Shah et al., 2007; 
Barzegar-Jalali et al., 2012). 
XRD studies
The XRD pattern of pure MLX, crospovidone, 
poloxamer, MLX SDs (SD2 and SD5), and physical mixture 
are exhibited in Figure 2. X-ray diffraction of MLX showed 
sharp peaks at 2θ values of 13°, 14.9°, 18.5° and 25.7°. 
The X-ray diffraction spectrum of crospovidone exhibited 
a halo pattern, indicating a completely amorphous state of 
these polymers. Moreover, the X-ray diffraction spectrum 
of poloxamer 188 showed characteristic peaks at 18.2° and 
25.1°. The intensity of the MLX characteristic peaks in the 
physical mixture of MLX and polymers reduced due to 
the polymer dilution effect, while a signiﬁcant decrease in 
the intensity of characteristic peaks of MLX in MLX SDs, 
compared to pure MLX, suggested a signiﬁcant reduction 
in MLX crystallinity due to MLX amorphization and its 
incorporation in the carrier structure (Barzegar-Jalali et 
al., 2012). 
Preparation and characterization of ODTs 
The optimized MLX SD, which showed the highest 
saturation solubility (SD2), was selected to develop MLX 
ODTs. The ODT compositions in this study are listed in 
Table III.
On a large scale, the flowability of powder blends 
could affect the content uniformity of tablets. Thus 
powder blends were evaluated for Hausner’s ratio and 
Carr’s index before tablet compression. Hausner’s ratio 
and Carr’s index of powder blends were less than 1.2 and 
11 respectively, indicating a good flowability of powder 
blends (Shah, Tawakkul, Khan, 2008). MLX ODTs were 
prepared by the direct compression method because it is 
an easy and low-cost method (Medina, Kumar, 2006). 
FIGURE 1 - The DSC thermograms of poloxamer 188, 
crospovidone, pure MLX, physical mixture of MLX and 
polymers and MLX SDs (SD2 and SD5).
FIGURE 2 - XRD pattern of pure MLX, poloxamer 188, 
crospovidone, their physical mixture and MLX SDs (SD2 and 
SD5).
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The average MLX content of the prepared MLX ODT 
formulations were in the range of 74.8±4.25-94.1±3.16% 
and met the United States Pharmacopeia (USP) content 
uniformity requirements (USP, 2007). 
Friability
Tablet friability could reflect the tablet’s physical 
strength. The acceptable friability range for ODTs was 
mentioned to be 0.95% to 1.5% (Mendes, Anaebonam 
1990). The friability of conventional tablets must be less 
than 1% (USP, 2006). The friability of the prepared MLX-
ODT formulations did not exceed 1.34±0.08% (Table 
III). Moreover, no tablet had cracked, split or broken in 
formulations. 
Disintegration time
ODTs should disintegrate rapidly after placement 
in the mouth, thus the disintegration time is one of 
the most crucial characteristics of ODTs. Moreover, 
ODTs should have sufficient hardness and friability to 
withstand handling without substantial breakage and 
attrition. Ideally, ODTs showed a disintegration time of 
60 s or less, and showed the hardness of at least 40 N 
(Ramtoola, Pabari, Kelly, 2008). However, increasing 
the hardness of tablets could increase the disintegration 
time and decrease the amount of dissolved drug after 
known time. One of the important aims of this study 
was the preparation of ODTs with hardness greater than 
40 N without any signiﬁcant effect on the disintegration 
time and the percentage of the dissolved MLX after 
30 min. Therefore, the crucial responses that were 
selected as dependent variables were disintegration 
time, hardness, and the percent of dissolved MLX in 
the dissolution media after 30 min. The results obtained 
for the disintegration time of the prepared MLX-ODT 
tablets are summarized in Tables III. Six formulations 
TABLE III - Factorial design of MLX ODTs (F1 to F8) and the response parameters
Ingredients 
(mg/tablet)
Formula code
F1 F2 F3 F4 F5 F6 F7 F8
MLX-SD 
(equivalent 
7.5 mg MLX) 
(mg)
24.3 24.3 24.3 24.3 24.3 24.3 24.3 24.3
Mannitol 
(mg) 76.8 92.16 71.8 86.16 76.8 92.16 71.8 86.16
Avicel (mg) 38.4 23.04 35.9 2154 38.4 23.04 35.9 21.54
Mannitol/
Avicel ratio 2 4 2 4 2 4 2 4
Crospovidone 
(mg) 7.5 7.5 15 15 7.5 7.5 15 15
Aspartam 
(mg) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Mg stearate 
(mg) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Total weight 
(mg) 150 150 150 150 150 150 150 150
Force (kN) low low low low high high high high
Hardness 23.25±5.8 25.75±4 22.42±5.5 17.87±3.6 44.87±4.3 45.5±5.4 45.75±6.1 34.37±2.1
Disintegration 
time 18±13.8 25±5 13.33±1.1 14.3±3.6 31.6±4.3 32.5±3.1 12±2 12.66±2.5
% of 
dissolved 
meloxicam 
after 30 min
76.36±3.4 79.33±4.9 77.2±3.06 80.4±1.6 77.8±4.3 80.16±2.5 78.1±3.91 82.66±5.1
Friability% 1.34±0.08 0.88±0.03 1±0.054 1.33±0.04 0.87±0.06 1.12±0.03 0.7±0.09 1.26±0.04
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showed a disintegration time of lower than 30 sec and 
two formulations showed a disintegration time more 
than 30 sec. F6 showed the longest disintegration time 
(32.5±3.1 sec) and F7 showed the shortest disintegration 
time (12±2 sec). An ANOVA analysis showed that only 
one factor, namely, percent of superdisintegrant (C) 
had signiﬁcant effects on the disintegration time of the 
prepared MLX ODTs at p < 0.0001 (Figure 3). The 
results show that the disintegration time decreased as 
the percentage of superdisintegrant increased. However, 
the mannitol–avicel ratio and compression force did 
not have signiﬁcant effects on the disintegration time. 
The resulting equation for responses, Y1 (disintegration 
time), is presented below:
Disintegration time = +40.58250 - 2.75850 * percent of 
superdisintegrant.
Hardness of MLX ODTs
The hardness of the prepared MLX-ODTs was in 
the range of 17.87–45.75 N (Table III) with the highest 
hardness values observed in F5, F6, F7, and F8 with the 
mean hardness values of 44.87±4.3, 45.5±5.4, 45.75±6.1, 
34.37±2.16 N respectively. An ANOVA analysis showed 
that only one factor, namely, compression force (A; p < 
0.0007), had a signiﬁcant effect on the hardness of the 
prepared MLX-ODTs (Figure 4). The results show that 
the hardness of tablets increased as the compression 
force was increased. Other factors (the percentage of 
superdisintegrant and mannitol–avicel ratio) did not 
have a signiﬁcant effect on the hardness of MLX ODTs. 
The resulting equation for responses, Y2 (hardness), is 
presented below:
Hardness = +32.47250 + 10.15000 * compression Force
In vitro dissolution studies
Figure 5 represents the dissolution proﬁles of the 
prepared MLX ODTs. According to the United States 
Pharmacopeia (USP), an MLX tablet should release 
70 percent of its drug content after 30 min. F4 and F8 
showed the highest percentage of MLX release after 30 
min; 80.4±1.6 and 82.66±5.1 respectively. This high 
amount of release could be due to the high amount of 
water-soluble mannitol and low amount of low water-
soluble avicel in their formulations. The use of a high 
amount of mannitol in tablet formulation could help the 
dissolution of poorly water-soluble drugs (Myers, Battist, 
Fuisz, 1995). Moreover, F4 and F8 released about 50% 
of their drug content only after 2 min. This burst release 
of MLX might be due to the effect of water-soluble 
mannitol, which could increase the degree of cracking 
and bursting (Shirai et al., 1994). An ANOVA analysis 
showed only one factor, namely, mannitol–avicel ratio 
(p < 0.0001) had a signiﬁcant effect on the percentage 
of dissolved MLX (after 30 min) from the prepared 
MLX ODTs (Figure 6). The results also showed that the 
percentage of MLX dissolved after 30 min increased 
as the mannitol–avicel ratio become greater. The 
compression force and percentage of super disintegrant 
did not show any significant effects on the percent of 
MLX released after 30 min. The resulting equation for 
responses, Y3 (percent of MLX that dissolved after 30 
min), is presented below:
Percent of dissolved meloxicam after 30 min   
= + 74.09250 + 1.63625 * mannitol – avicel ratio
FIGURE 4 - Effect of compression force on the hardness of 
MLX ODT.
FIGURE 3 - Effect of percent of superdisintegrant on the 
disintegration time of MLX ODT.
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Optimum ODTs formulation
Based on the responses, the software was used 
to perform a hot spot analysis to obtain the optimum 
formulation variables (compression force, percent of 
superdisintegrant and mannitol/avicel ratio) to produce 
ODTs with the desired characteristics. The request was 
to minimize the disintegration time, and maximize 
the hardness and percent of released MLX from the 
formulation after 30 min. Therefore; the F8 formulation 
was determined to be the optimal formulation. 
CONCLUSION
The main goal of a solid dispersion drug delivery 
system is to improve the water solubility of poorly water-
soluble drugs. Solid dispersion prepared by the melting 
method with crospovidone and poloxamer 188 with 
special physicochemical properties have shown to be one 
of the most attractive approaches to enhance the solubility 
of the poorly water-soluble drug meloxicam. On the other 
hand, orally disintegrating tablets prepared from solid 
dispersion represent a promising approach to improving 
the solubility and slow onset of action of drugs, especially 
for BCS Class II of drugs, including meloxicam with poor 
dissolution properties. The present study demonstrated 
an effective method for the preparation of a suitable 
dosage form of meloxicam with improved solubility and 
onset of action. This dosage form could be suitable for 
administration in elderly patients with dysphagia.
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